KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GoodRx Holdings (GDRX) Share-based Compensation (2019 - 2025)

GoodRx Holdings' Share-based Compensation history spans 7 years, with the latest figure at $17.9 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 14.5% year-over-year to $17.9 million; the TTM value through Dec 2025 reached $76.6 million, down 22.62%, while the annual FY2025 figure was $76.6 million, 22.62% down from the prior year.
  • Share-based Compensation for Q4 2025 was $17.9 million at GoodRx Holdings, down from $18.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $46.5 million in Q1 2021 and bottomed at $16.8 million in Q4 2021.
  • The 5-year median for Share-based Compensation is $26.4 million (2024), against an average of $27.2 million.
  • The largest YoY upside for Share-based Compensation was 2005.25% in 2021 against a maximum downside of 94.13% in 2021.
  • A 5-year view of Share-based Compensation shows it stood at $16.8 million in 2021, then surged by 75.08% to $29.4 million in 2022, then rose by 10.99% to $32.6 million in 2023, then tumbled by 35.8% to $21.0 million in 2024, then fell by 14.5% to $17.9 million in 2025.
  • Per Business Quant, the three most recent readings for GDRX's Share-based Compensation are $17.9 million (Q4 2025), $18.1 million (Q3 2025), and $21.4 million (Q2 2025).